Analytical Data
-
Gene name
BCAS3
- Application
-
Alternative Names
GAOB1; MAAB; GAOB1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9H6U6
-
Expression Region
Met230~Gly546
-
Molecular Weight
42kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BCAS3 (Breast Cancer Amplified Sequence 3) is a gene that has garnered significant interest due to its potential role in cancer biology, particularly in breast cancer. Initially identified as an amplified sequence in breast cancer tissues, BCAS3 is believed to contribute to tumor progression and metastasis. Research has shown that BCAS3 is overexpressed in various cancer types, which points to its involvement as a potential oncogene. Moreover, studies suggest that BCAS3 may play a role in modulating cell growth, survival, and invasive properties, highlighting its significance in cancer development and therapeutic resistance. The creation of recombinant BCAS3 protein allows for detailed functional studies, enabling researchers to elucidate its biological mechanisms and interactions within cellular pathways. This understanding could lead to the identification of novel diagnostic markers or therapeutic targets, fostering advancements in personalized medicine approaches for breast and other cancers. The ongoing exploration of BCAS3's roles in cancer also emphasizes the need for targeted research to develop effective strategies to inhibit its function in malignancies, providing hope for improved treatment options for patients.
